Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1756-8722
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia ; volume:12 ; number:1 ; day:28 ; month:6 ; year:2019 ; pages:1-14 ; date:12.2019
Journal of hematology & oncology ; 12, Heft 1 (28.6.2019), 1-14, 12.2019
- Urheber
-
Brzezinka, Krzysztof
Nevedomskaya, Ekaterina
Lesche, Ralf
Steckel, Michael
Eheim, Ashley L.
Haegebarth, Andrea
Stresemann, Carlo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s13045-019-0749-y
- URN
-
urn:nbn:de:101:1-2019102313422569342731
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
08.10.20252025, 10:16 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Brzezinka, Krzysztof
- Nevedomskaya, Ekaterina
- Lesche, Ralf
- Steckel, Michael
- Eheim, Ashley L.
- Haegebarth, Andrea
- Stresemann, Carlo
- SpringerLink (Online service)
Ähnliche Objekte (12)
RNA binding proteins in MLL-rearranged leukemia
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Using genome editing to model MLL rearranged leukemias
MLL-r Leukemia
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
Molecular pathogenesis of disease progression in MLL-rearranged AML
Identification of potential targets for palbociclib combination therapy in the context of MLL-rearranged acute myeloid leukemia
A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Transient spontaneous remission in congenital MLL-AF10 rearranged acute myeloid leukemia presenting with cardiorespiratory failure and meconium ileus
RNA binding proteins in MLL-rearranged leukemia
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Using genome editing to model MLL rearranged leukemias
MLL-r Leukemia
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
Molecular pathogenesis of disease progression in MLL-rearranged AML
Identification of potential targets for palbociclib combination therapy in the context of MLL-rearranged acute myeloid leukemia
A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair
Transient spontaneous remission in congenital MLL-AF10 rearranged acute myeloid leukemia presenting with cardiorespiratory failure and meconium ileus
RNA binding proteins in MLL-rearranged leukemia
Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia
FBXO22 promotes leukemogenesis by targeting BACH1 in MLL-rearranged acute myeloid leukemia
NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia
Using genome editing to model MLL rearranged leukemias
MLL-r Leukemia
The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia
Molecular pathogenesis of disease progression in MLL-rearranged AML
Identification of potential targets for palbociclib combination therapy in the context of MLL-rearranged acute myeloid leukemia
A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction
Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair